CommercialCoverageMedium impact
08.01.51c, Canakinumab (Ilaris®)
Independence Blue Cross·Rheumatology, Oncology, Allergy & Immunology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
The policy for Canakinumab (Ilaris®) medication coverage has been updated and will be reissued effective May 28, 2025. This is a recent pharmacy policy change that may affect coverage criteria, prior authorization requirements, or billing procedures for this specialty medication used to treat inflammatory conditions.
Action Required
By May 28, 2025: Billing team must review the updated Canakinumab (Ilaris®) policy at the provided URL to understand new coverage criteria, prior authorization requirements, or documentation needs. Update billing procedures and inform providers of any changes to ensure continued coverage for patients receiving this medication.